Medicure (OTCMKTS:MCUJF – Get Free Report) is anticipated to announce its results after the market closes on Thursday, November 19th. Analysts expect the company to post earnings of ($0.0220) per share and revenue of $5.08 million for the quarter.
Medicure (OTCMKTS:MCUJF – Get Free Report) last announced its earnings results on Friday, August 14th. The company reported ($0.10) EPS for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.05). The firm had revenue of $5.36 million for the quarter, compared to analyst estimates of $2.45 million. Medicure had a negative net margin of 23.14% and a negative return on equity of 54.55%.
Medicure Trading Down 1.3%
OTCMKTS MCUJF opened at $2.66 on Tuesday. The company has a debt-to-equity ratio of 0.02, a quick ratio of 0.64 and a current ratio of 0.97. The stock’s 50 day simple moving average is $2.43 and its 200-day simple moving average is $1.25. Medicure has a 1-year low of $0.67 and a 1-year high of $3.45.
Medicure Company Profile
Medicure Inc. is a Canadian pharmaceutical company focused on developing and commercializing products for cardiovascular disease. Through its U.S. operations, the company markets Aggrastat (tirofiban), an intravenous antiplatelet medicine used to help reduce the risk of certain cardiovascular events in patients with acute coronary syndrome, and Zypitamag (pitavastatin), a medicine for managing elevated cholesterol. The company serves customers in the United States and has historically focused its commercial activities on the U.S. cardiovascular market.
See Also
- Five stocks we like better than Medicure
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Medicure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medicure and related companies with MarketBeat.com's FREE daily email newsletter.
